Search

Your search keyword '"O’Neil, Erika R."' showing total 33 results
Start Over Author "O’Neil, Erika R."
33 results on '"O’Neil, Erika R."'

2. An evaluation of the outcomes associated with peritoneal catheter use in neonates undergoing cardiac surgery: A multicenter study

Author

Zang, Huaiyu, Winlaw, David, Bailly, David, Goldstein, Stuart, Gist, Katja, Brandewie, Katie L., Bhat, Priya N., Diddle, John W., Ghbeis, Muhammad, Prodhan, Parthak, Garcia, Xiomara, Ramer, Shannon, Albertson, Mindy, Rodriquez, Zahidee, Lukacs, Mary, Gaies, Michael, Freytag, Joshua, Sammons, Amanda, Abraha, Hideat, Butcher, John, Zanaboni, Dominic, Sanchez de Toledo, Joan, Domnina, Yuliya A., Saenz, Lucas, Baust, Tracy, Kluck, Jane, Sasaki, Jun, Raees, Aanish, O'Neil, Erika R., Lasa, Javier J., Phillips, Patrick A., Hock, Kristal M., Valentine, Kevin, Tadphale, Sachin, Buckley, Jason R., Schroeder, Luke, Clarke, Shanelle, Zhang, Wenying, Smith, Andrew, Absi, Mohammed, Askenazi, David J., Duncan, Linda, Bertrandt, Rebecca A., Sosa, Lisa J., O’Neal, Erika R., Doman, Tammy, Viers, Suzanne, Smith, Andrew H., Bailly, David K., Kwiatkowski, David M., Alten, Jeffrey A., Mah, Kenneth E., Selewski, David T., Raymond, Tia T., Afonso, Natasha S., Blinder, Joshua J., Coghill, Matthew T., Cooper, David S., Koch, Joshua D., Krawczeski, Catherine D., Morales, David L.S., Neumayr, Tara M., Rahman, A.K.M. Fazlur, Reichle, Garrett, Tabbutt, Sarah, Webb, Tennille N., and Borasino, Santiago

Published
2024
Full Text
View/download PDF

4. Extracorporeal Membrane Oxygenation for COVID-19: Collaborative Experience From the Texas Medical Center in Houston With 2 Years Follow-Up

Author

Akkanti, Bindu, Suarez, Erik E., O’Neil, Erika R., Rali, Aniket S., Hussain, Rahat, Dinh, Kha, Tuazon, Divina M., MacGillivray, Thomas E., Diaz-Gomez, Jose L., Simpson, Leo, George, Joggy K., Kar, Biswajit, Herlihy, J. Patrick, Shafii, Alexis E., Gregoric, Igor D., Masud, Faisal, and Chatterjee, Subhasis

Published
2022
Full Text
View/download PDF

5. An evaluation of the outcomes associated with peritoneal catheter use in neonates undergoing cardiac surgery: A multicenter study

Author

Kwiatkowski, David M., primary, Alten, Jeffrey A., additional, Mah, Kenneth E., additional, Selewski, David T., additional, Raymond, Tia T., additional, Afonso, Natasha S., additional, Blinder, Joshua J., additional, Coghill, Matthew T., additional, Cooper, David S., additional, Koch, Joshua D., additional, Krawczeski, Catherine D., additional, Morales, David L.S., additional, Neumayr, Tara M., additional, Rahman, A.K.M. Fazlur, additional, Reichle, Garrett, additional, Tabbutt, Sarah, additional, Webb, Tennille N., additional, Borasino, Santiago, additional, Zang, Huaiyu, additional, Winlaw, David, additional, Bailly, David, additional, Goldstein, Stuart, additional, Gist, Katja, additional, Brandewie, Katie L., additional, Bhat, Priya N., additional, Diddle, John W., additional, Ghbeis, Muhammad, additional, Prodhan, Parthak, additional, Garcia, Xiomara, additional, Ramer, Shannon, additional, Albertson, Mindy, additional, Rodriquez, Zahidee, additional, Lukacs, Mary, additional, Gaies, Michael, additional, Freytag, Joshua, additional, Sammons, Amanda, additional, Abraha, Hideat, additional, Butcher, John, additional, Zanaboni, Dominic, additional, Sanchez de Toledo, Joan, additional, Domnina, Yuliya A., additional, Saenz, Lucas, additional, Baust, Tracy, additional, Kluck, Jane, additional, Sasaki, Jun, additional, Raees, Aanish, additional, O'Neil, Erika R., additional, Lasa, Javier J., additional, Phillips, Patrick A., additional, Hock, Kristal M., additional, Valentine, Kevin, additional, Tadphale, Sachin, additional, Buckley, Jason R., additional, Schroeder, Luke, additional, Clarke, Shanelle, additional, Zhang, Wenying, additional, Smith, Andrew, additional, Absi, Mohammed, additional, Askenazi, David J., additional, Duncan, Linda, additional, Bertrandt, Rebecca A., additional, Sosa, Lisa J., additional, O’Neal, Erika R., additional, Doman, Tammy, additional, Viers, Suzanne, additional, Smith, Andrew H., additional, and Bailly, David K., additional

Published
2024
Full Text
View/download PDF

6. Definitions of adverse events associated with extracorporeal membrane oxygenation in children: results of an international Delphi process from the ECMO-CENTRAL ARC

Author

Alexander, Peta M A, Di Nardo, Matteo, Combes, Alain, Vogel, Adam M, Antonini, Marta Velia, Barrett, Nicholas, Benedetti, Giulia M, Bettencourt, Amanda, Brodie, Daniel, Gómez-Gutiérrez, René, Gorga, Stephen M, Hodgson, Carol, Kapoor, Poonam Malhotra, Le, Jennifer, MacLaren, Graeme, O’Neil, Erika R, Ostermann, Marlies, Paden, Matthew L, Patel, Neil, Rojas-Peña, Alvaro, Said, Ahmed S, Sperotto, Francesca, Willems, Ariane, Vercaemst, Leen, Yoganathan, Ajit P, Lorts, Angela, del Nido, Pedro J, Barbaro, Ryan P, Abecasis, Francisco, Al Foudri, Huda, Anders, Marc M., Angus, Derek C., Annich, Gail M., Arachchillage, Deepa J., Akcan-Arikan, Ayse, Armstrong, Aimee K., Balcells, Joan, Barrett, Meredith, Bartlett, Robert H., Belda-Hofheinz, Sylvia, Bembea, Melania M., Best, Derek J., Bonadonna, Desiree, Boonstra, Philip S., Brogan, Thomas V, Brown, Katherine L, Butragueño-Laiseca, Laura, Butt, Warwick W., Camporota, Luigi, Cardenas, Barbara, Cascarano, Maria T., Caspi, Joseph, Chen, Eric, Chiletti, Roberto, Colombo, Giovanna G., Conte, Marisa L., Crowe, Liz, Cvetkovic, Mirjana, Dalton, Heidi J., Daverio, Marco, Davidson, Mark G., Davis, Carl, DiGeronimo, Robert J., Egbunine, Ariel, Ellis, W. Cory, Fan, Eddy, Foster, Claire C, Fraser, John F., Friedman, Matthew L., Furlong-Dillard, Jamie, Fynn-Thompson, Francis, Garcia, Alejandro V., Geppert, Jeffery, Gillette, Nicole, Grazioli, Lorenzo, Greene, Christina L, Guerguerian, Anne-Marie, Guilliams, Kristin P., Haji Fortis, Jumana Y., Hao, Jianming, Heinsar, Silver, Hejduk, Mark W., Himebauch, Adam S., Horvat, Christopher M., Hoskote, Aparna, Hou, Xiaotong, Hyslop, Robert W., Ibrahim, Nicole, Ito, Takuya, Karagiannidis, Christian, Karam, Oliver, Kaushik, Shubhi, Kilbaugh, Todd J., Kim-Campbell, Nahmah, Kirsch, Roxanne E, Kormos, Robert L., Kornberger, Angela, Krucoff, Mitchell W., Lakshminrusimha, Satyan, LaRovere, Kerri L, Leger, Pierre-Louis, Levy, Philip T., Lorusso, Roberto, Lyster, Haifa, Malone, Matthew P., McMullan, D. Michael, Mečířová, Soña, Mehran, Roxana, Merz, Scott I., Mochizuki, Shuichi, Moler, Frank W., Molla, Kalkidan, Monagle, Paul, Morgan, Gareth J., Morgan, Catherine, Morice, Marie-Claude, Muszynski, Jennifer A., Najaf, Tasnim A., Nellis, Marianne E., Newburger, Jane W., O'Rourke, P. Pearl, Ostadal, Petr, Ozment, Caroline P., Pagani, Francis D., Peek, Giles J., Polito, Angelo, Priest, John R., Raman, Lakshmi, Rintoul, Natalie E., Roy, Nathalie, Rubin, Juli, Rumford, Martha, Rycus, Peter, Ryerson, Lindsay M., Sakamoto, Wakako, Segura-Matute, Susana, Shekar, Kiran, Spinella, Philip C., Spitzer, Ernest, Starr, Joanne P., Stead, Christine, Steffen, Katherine, Steiner, Marie E., Tan, Lucy, Tasker, Robert C., Taylor, J. Michael, Thiagarajan, Ravi R., Tonna, Joseph E., Ubertini, Gina M., van Leeuwen, Grace, Vang, Eric, Ventetuolo, Corey E., Venugopal, Prem S., Weinberg, Allison, Westrope, Claire, Wu, Changfu, Wylie, Gillian, Zeymer, Uwe, Zivick, Elizabeth E., and Zochios, Vasileios

Abstract

Extracorporeal membrane oxygenation (ECMO) is a high-risk and low-volume life support with increasing clinical study. However, heterogenous outcome definitions impede data assimilation into evidence to guide practice. The Academic Research Consortium (ARC), an international collaborative forum committed to facilitating the creation of stakeholder-driven consensus nomenclature and outcomes for clinical trials of medical devices, supported the ECMO Core Elements Needed for Trials Regulation And quality of Life (ECMO-CENTRAL) ARC. The ECMO-CENTRAL ARC was assembled to develop definitions of paediatric ECMO adverse events for use in clinical trials and regulatory device evaluation. An initial candidate list of ECMO adverse events derived from the mechanical circulatory support ARC was supplemented with a review of ECMO-relevant adverse event definitions collated from literature published between Jan 1, 1988, and Feb 20, 2023. Distinct teams of international topic experts drafted separate adverse event definitions that were harmonised to existing literature when appropriate. Draft definitions were revised for paediatric ECMO relevance with input from patients, families, and an international expert panel of trialists, clinicians, statisticians, biomedical engineers, device developers, and regulatory agencies. ECMO-CENTRAL ARC was revised and disseminated across research societies and professional organisations. Up to three rounds of internet-based anonymous surveys were planned as a modified Delphi process. The expert panel defined 13 adverse event definitions: neurological, bleeding, device malfunction, acute kidney injury, haemolysis, infection, vascular access-associated injury, non-CNS thrombosis, hepatic dysfunction, right heart failure, left ventricular overload, lactic acidaemia, and hypoxaemia. Definitional structure varied. Among 165 expert panel members, 114 were eligible to vote and 111 voted. Consensus was achieved for all proposed definitions. Agreement ranged from 82% to 95%. ECMO-CENTRAL ARC paired rigorous development with methodical stakeholder involvement and dissemination to define paediatric ECMO adverse events. These definitions will facilitate new research and the assimilation of data across clinical trials and ECMO device evaluation in children.

Published
2024
Full Text
View/download PDF

10. Pediatric Highlights From the Extracorporeal Life Support Organization Registry: 2017–2022

Author

O’Neil, Erika R., primary, Guner, Yigit, additional, Anders, Marc M., additional, Priest, John, additional, Friedman, Matthew L., additional, Raman, Lakshmi, additional, Di Nardo, Matteo, additional, Alexander, Peta, additional, Tonna, Joseph E., additional, Rycus, Peter, additional, Thiagarajan, Ravi R., additional, Barbaro, Ryan, additional, and Sandhu, Hitesh S., additional

Published
2023
Full Text
View/download PDF

13. Outcomes Following Extracorporeal Membrane Oxygenation for Severe COVID-19 in Pregnancy or Post Partum

Author

Byrne, John J., primary, Shamshirsaz, Amir A., additional, Cahill, Alison G., additional, Turrentine, Mark A., additional, Seasely, Angela R., additional, Eid, Joe, additional, Rouse, Caroline E., additional, Richley, Michael, additional, Raghuraman, Nandini, additional, Naqvi, Mariam, additional, El-Sayed, Yasser Y., additional, Badell, Martina L., additional, Cheng, CeCe, additional, Liu, James, additional, Adhikari, Emily H., additional, Patel, Soha S., additional, O’Neil, Erika R., additional, and Ramsey, Patrick S., additional

Published
2023
Full Text
View/download PDF

24. Safely repositioning dual-lumen ECMO cannulas with a transfemoral lasso snare.

Author

O'Neil, Erika R, Coleman, Ryan D, Vogel, Adam M, Chartan, Corey A, and Kukreja, Kamlesh U

Subjects
*SAFETY, *ECHOCARDIOGRAPHY, *HUMAN research subjects, *ULTRASONIC imaging, *HEMATOMA, *EXTRACORPOREAL membrane oxygenation, *OXYGEN saturation, *INFORMED consent (Medical law), *FLUOROSCOPY, *TREATMENT effectiveness, *JUGULAR vein, *DESCRIPTIVE statistics, *CATHETERIZATION, *CATHETERS, *HEMORRHAGE, *CHILDREN
Abstract

Introduction: Dual-lumen cannulas were designed to provide venovenous extracorporeal membrane oxygenation (VV ECMO) with single-vessel access. Anatomic and size considerations may make appropriate placement challenging in children. Dual-lumen cannulas are repositioned in 20–69% of pediatric patients, which can be difficult without transient discontinuation of ECMO support. Methods: We repositioned three dual-lumen ECMO cannulas introduced via the right internal jugular vein using a transfemoral snare technique under real-time ultrasound and fluoroscopy. Results: Two of three patients were supported on VV ECMO and one on veno-veno-arterial (VV-A) ECMO. Two of the three patients had their dual-lumen cannula repositioned under ultrasound and fluoroscopy guidance and one was repositioned just with ultrasound. No patient experienced a complication from the transfemoral snare technique such as femoral hematoma, hemorrhage or limb ischemia. Conclusion: We describe three patients who successfully had dual-lumen cannulas repositioned without cessation of ECMO using a transfemoral "lasso" technique. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

27. Extracorporeal Membrane Oxygenation Support for Antineutrophil Cytoplasmic Antibody-associated Vasculitides: An ELSO Registry Analysis

Author

O’Neil, Erika R., Quinn, Rachel E., Olson, Taylor L., Rycus, Peter T., Anders, Marc M., Chartan, Corey A., Vogel, Tiphanie P., Silva-Carmona, Manuel, and Coleman, Ryan D.

Abstract

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides with pulmonary involvement include granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis, and can present with life-threatening pulmonary hemorrhage in up to 40% of patients. Mortality in those patients who require intubation and mechanical ventilation can reach 77%. Extracorporeal membrane oxygenation (ECMO) can be used to support these patients through definitive diagnosis and treatment, although minimizing the risk of ventilator-induced lung injury. We aimed to determine factors associated with favorable outcomes in patients with (ANCA)-associated vasculitides supported on ECMO. We performed a retrospective observational study using the Extracorporeal Life Support Organization registry of pediatric and adult patients with ANCA-associated vasculitis supported on ECMO from 2010 to 2020. One hundred thirty-five patients were included for analysis. Many patients had renal involvement (39%) in addition to pulmonary involvement (93%). Survival was 73% in AAV patients supported on ECMO. The presence of pulmonary hemorrhage was not associated with worse outcomes in our cohort. Older age, the use of venoarterial ECMO, ECMO-cardiopulmonary resuscitation, or sustaining a cardiac arrest before ECMO was associated with decreased survival. In conclusion, venovenous ECMO should be considered as a supportive bridge to definitive diagnosis and treatment in (ANCA)-associated vasculitides, regardless if pulmonary hemorrhage is present.

Published
2022
Full Text
View/download PDF

29. Oncogenic GOPC-ROS1Fusion Identified in a Congenital Glioblastoma Case

Author

Whiteway, Susan L., Betts, Aaron M., O’Neil, Erika R., Green, Adam L., Gilani, Ahmed, Orr, Brent A., and Mathis, Derek A.

Abstract

Congenital glioblastoma (GBM) is a rare brain tumor of infancy. While histologically they resemble pediatric and adult GBM, growing evidence suggests a distinct molecular profile. We report the case of a 7-day-old infant female with congenital GBM found to harbor a GOPC-ROS1 fusion. She underwent surgical resection, moderate-intensity chemotherapy without radiation, and remains disease-free 4 years from completion of therapy. While the frequency of this mutation is not known, the identification of this oncogenic driver may provide insight into the pathogenesis of GBM in this age group and may serve as a molecular target for select patients.

Published
2020
Full Text
View/download PDF

32. Extracorporeal Membrane Oxygenation Support for Influenza A: Retrospective Review of the Extracorporeal Life Support Organization Registry Comparing H1N1 With Other Subtypes.

Author

O'Neil ER, Lin H, Li M, Shekerdemian L, Tonna JE, Barbaro RP, Abella JR, Rycus P, MacLaren G, Anders MM, and Alexander PMA

Abstract

Objectives: Although there is a substantial published experience of extracorporeal membrane oxygenation during the H1N1 pandemic, less is known about the use of extracorporeal membrane oxygenation in patients with other subtypes of the influenza A virus. We hypothesized that the severity of illness and survival of patients supported with extracorporeal membrane oxygenation would differ for those with H1N1 influenza A compared with other subtypes of influenza A., Design Setting Patients: Retrospective study of extracorporeal membrane oxygenation-supported adults (> 18 yr) with influenza A viral infection reported to the Extracorporeal Life Support Organization Registry between 2009 and 2019. We describe the frequency and compare characteristics and factors associated with in-hospital survival using a least absolute shrinkage and selection operator regression analysis., Main Outcomes and Measures: Of 2,461 patients supported with extracorporeal membrane oxygenation for influenza A, 445 had H1N1, and 2,004 had other subtypes of influenza A. H1N1 was the predominant subtype between 2009 and 2011. H1N1 patients were younger, with more severe illness at extracorporeal membrane oxygenation cannulation and higher reported extracorporeal membrane oxygenation complications than those with other influenza A subtypes. Patient characteristics including younger age and higher weight and patient management characteristics including longer ventilation duration before extracorporeal membrane oxygenation were associated with worse survival. Extracorporeal membrane oxygenation complications were associated with reduced survival. There was no difference in survival to hospital discharge according to influenza subtype after adjusting for other characteristics., Conclusions: Patients supported with extracorporeal membrane oxygenation for H1N1 were younger, with more severe illness than those supported for other influenza A subtypes. Survival to hospital discharge was associated with patient characteristics, management characteristics, and extracorporeal membrane oxygenation complications but was not impacted by the specific influenza A subtype., Competing Interests: Dr. Tonna is supported by a Career Development Award from the National Institutes of Health/National Heart, Lung, and Blood Institute (K23 HL141596). Dr. Tonna received speaker fees and travel compensation from LivaNova and Philips Healthcare, unrelated to this work. Dr. Barbaro reports grants from the National Institutes of Health (R01 HL153519-ASCEND; K12 HL138039-TACTICAL; R01 HD01543-Pediatric Implantable Artificial Lung) outside the submitted work; he also discloses that he is the Extracorporeal Life Support Organization Registry Chair. Dr. Alexander reports grants from the National Institutes of Health (1R13HD104432-01 Pediatric Extracorporeal membrane oxygenation Anticoagulation CollaborativE) outside the submitted work. The remaining authors have disclosed that they do not have any conflicts of interest., (Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.)

Published
2021
Full Text
View/download PDF

33. Inhaled Tranexamic Acid As a Novel Treatment for Pulmonary Hemorrhage in Critically Ill Pediatric Patients: An Observational Study.

Author

O'Neil ER, Schmees LR, Resendiz K, Justino H, and Anders MM

Abstract

Objectives: To describe the use of inhaled or endotracheally instilled tranexamic acid in critically ill pediatric patients for the treatment of pulmonary hemorrhage, which can be severe, life-threatening, and include potentially high-risk management procedures., Design: Retrospective observational study from 2011-2018 with patients followed until hospital discharge., Setting: Free-standing children's hospital with an annual ICU volume of more than 3,500 yearly admissions., Patients: Pediatric patients, ages 0 to 18 years, admitted to an ICU and who received at least one dose of inhaled or endotracheally instilled tranexamic acid were included., Interventions: Inhaled or endotracheally instilled tranexamic acid., Measurements and Main Results: This study described the efficacy and adverse effects of patients who received inhaled or endotracheally instilled tranexamic acid. A total of 19 patients met inclusion criteria; median age was 72 months (11-187 mo), most patients were female (11, 58%), and almost half our patients (8, 42%) had congenital heart disease. Nine of 19 encounters (47%) had diffuse alveolar hemorrhage, four (21%) had pulmonary hemorrhage related to major aortopulmonary collateral arteries, two (11%) had mucosal airway bleeding, two (11%) were iatrogenic, one had a pulmonary embolism, and one patient did not have their etiology of pulmonary hemorrhage determined. Cessation of pulmonary hemorrhage was achieved in 18 of 19 patients (95%) with inhaled tranexamic acid with no major adverse events recorded., Conclusions and Relevance: We demonstrate that inhaled tranexamic acid may be safely used to treat pulmonary hemorrhage from varied etiologies in critically ill pediatric patients. Prospective studies are required in this vulnerable population to determine optimal dosing and delivery strategies, as well as to define any differential effect according to etiology., Competing Interests: The authors have disclosed that they do not have any potential conflicts of interest., (Copyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results